

# Upper and Lower Extremity CTA

**Richard L. Hallett, MD**

Associate Clinical Professor of Radiology  
University of Arizona College of Medicine - Phoenix  
Banner University Medical Center – Phoenix




**Banner**  
**University Medical Center**  
Phoenix

# OUTLINE

- Lower Extremity CTA
  - Indications
  - Technique/Results
  - Cases
- Upper Extremity CTA
  - Indications
  - Technique
  - Cases

**Handout:** [stanford.edu/~hallett](https://stanford.edu/~hallett)  
choose folder “RSNA2023”



# Lower Extremity CTA

# Lower Extremity CTA - Indications

- PAD
  - IC
  - CLI
  - Acute ischemia
  - Response to Tx / complications
- Trauma
- Other
  - Vasculitis / CTD
  - Buerger's
  - AVF/AVM
  - Surgical planning (free flap)



# Diagnosis and Staging of PAD

= symptoms + ABI

\* poor correlation of symptoms and ABI with number, location and severity of lesions

Example: calf claudication can be caused by isolated disease or combination of iliac and/or femoropopliteal lesions



# Goal of CTA imaging in PAD

Goal of LE CTA Imaging is **NOT**  
diagnosis / staging

The role of CTA is to map lesions  
to patient symptoms  
guide treatment planning



# Technique - LE CTA

- Scan Acquisition
- Contrast Medium Injection



@CTterrific

Handout: [stanford.edu/~hallett](https://stanford.edu/~hallett) choose folder “RSNA2023”

# Lower Extremity CTA: Scan Acquisition

## Scanning Range 1

celiac artery (~T12) → toes  
(105 – 130 cm)


## Optional Scanning Range 2

above the knees → toes

Always pre-programmed, but only initiated  
by RT if no contrast in pedal vessels


## Recons:

FOV = greater trochanters



# Contrast injection for peripheral CTA

- Aorto-popliteal transit time: 4-24 sec (10 sec)
  - = Contrast (blood) speed: 29-177 mm/s
  - Slow scanner down, otherwise can overrun bolus
- Biphasic injections and weight-based CM dosing yield more consistent enhancement profile



# Integrated Scanning-Injection Protocol: (Siemens)

- Scan time: 40s for ALL patients (pitch variable)
- Inj.duration: 35s for ALL patients
- Delay: bolus triggering

## WEIGHT

## BIPHASIC INJECTION

<55kg

20 mL (4.0mL/s) + 96 mL (3.2mL/s)

<65kg

23 mL (4.5mL/s) + 108 mL (3.6mL/s)

**75kg**


**25 mL (5.0mL/s) + 120 mL (4.0mL/s)**

>85kg

28 mL (5.5mL/s) + 132 mL (4.4mL/s)

>95kg

30 mL (6.0mL/s) + 144 mL (4.8mL/s)



# Efficacy of LE CTA in PAD

Handout: [stanford.edu/~hallett](https://stanford.edu/~hallett)  
choose folder "RSNA2023"



# CTA: Diagnostic Performance vs. DSA

Performance

CT Channels	Sens (95% CI)	Spec (95% CI)
2-4	92 (88-96)	98 (95-99)
16-64	97 (95-98)	98 (96-99)

Detection of  $\geq 50\%$   
 Stenosis or Occlusion  
 By Anatomical Region

Vessels	Sens (95% CI)	Spec (95% CI)
Aortoiliac	96 (91-99)	98 (95-99)
Femoropopliteal	97 (95-99)	94 (85-99)
Trifurcation	95 (85-99)	91 (79-97)

# Management of IC and CLI by CTA

- Treated using TASC II guidelines
  - 49 conservative TX
  - 87 Endovascular
  - 38 surgery
  - 17 hybrid
- Tx recommendations from CTA same as DSA in all but ONE

# Recent Advance: Dual Energy/ Dual Detector CT

- Dual-Layer Spectral Detector CT<sup>1</sup>:
  - VMI best at 40 keV; 50% less CM outperforms standard CTA runoff
- PCCT:
  - VMI 40 – 60 keV – all better CNR/SNR/SEQ than standard 80-100 kVp<sup>2</sup>
- VMI also better for diabetic patient runoff <sup>3</sup>

<sup>1</sup> Kristiansen CH, et al. *Eur Radiol* 2023; 33:6033-44.

<sup>2</sup> Ripple K, et al. *Eur J Radiol* 2023; 158: 110645

<sup>3</sup> Bucolo GM et al. *Diagnostics* 2023; 13, 1790

# Recent Advance: High Spatial Resolution CT

- Better:
  - Wall definition
  - Noise
  - Diagnostic confidence
- More gains in calf vessels vs. fem-pop
- Maybe not better diagnostic accuracy for stenosis?<sup>1</sup>

<sup>1</sup>Onishi H, et al. *Radiology* 2018 (289) 255-260

Wang J, Fleischmann D. *Radiology* 2018 (289) 261-262

Schwartz FR, et al. *Eur Radiol.* 2023 Jun 29. doi: 10.1007/s00330-023-09841-4



512

Area: 51.62 mm.sq  
Mean: -161.39  
Max: -119  
Min: -202  
SDev: 14.77

10.00mm/div

10.00mm/div



1024

Area: 44.68 mm.sq  
Mean: -148.41  
Max: -128  
Min: -166  
SDev: 7.72


512

1024

# Cases – Lower Extremity



# Trauma




# CTA for stent assessment

- Most stents assessable (76%) by CTA
  - Gold / platinum markers
  - Motion
  - Strecker stent (Tantalum): Increased luminal density <sup>2</sup>
- If evaluable, **sens/spec ~ 95%** for significant in-stent restenosis (vs. DSA)




<sup>1</sup> Li X, et al. *Eur J Radiol* 2010; 98-103

<sup>2</sup> Strotzer, *Invest. Radiol.* 2001;36(11)



# Acute R leg pain



# UPPER EXTREMITY CTA




@CTterrific

Handout: [stanford.edu/~hallett](https://stanford.edu/~hallett) choose  
folder "RSNA2023"



# Upper Extremity Vascular Pathology

- Acute trauma (penetrating, crush, MVA, GSW)
  - Ischemia, thromboembolic
  - Aneurysms/PSA/AVM/vascular masses
  - Vasculitis
  - Hemodialysis fistulae/grafts
  - Raynauds /connective tissue disease
  - Anatomic mapping (radial flap)
- 

# UE CTA: Injection / Scan Technique

- **Non-trauma:** Supine, arm abducted and externally rotated, hand flat and fingers fanned (tape).
  - **Trauma:** arm at side, position near isocenter
- Inject contralateral arm, use saline flush
- Scan carina → fingertips
- Induce hyperemia:
  - BP cuff or squeeze ball x 1 min;
  - Warm compress
  - SL NTG



# UE CTE Contrast Injection


**(5 SEC LESS THAN LE)**

Body Weight (kg)	Phase I	Phase II	Total Contrast Medium Volume (mL)
<55	20 mL @ 4.0 mL/s	80 mL @ 3.2 mL/s	100
<65	23 mL @ 4.5 mL/s	90 mL @ 3.6 mL/s	113
<b>~75</b>	<b>25 mL @ 5.0 mL/s</b>	<b>100 mL @ 4.0 mL/s</b>	<b>125</b>
>85	28 mL @ 5.5 mL/s	110 mL @ 4.4 mL/s	138
>95	30 mL @ 6.0 mL/s	120 mL @ 4.8 mL/s	150

# Cases – Upper Extremity




Prior crush injuries,  
cool fingers



# Hand/ Finger AVM




# Takayasu Arteritis





Re-do  
HD  
fistula




- vQSS: PHCA injury w/ aneurysm and thrombus



- vQSS: Distal embolic disease to princeps pollicis a. and PDAs



# Hypothenar Hammer Syndrome



*Courtesy Minhaj Khaja MD, MBA  
Univ. of Michigan*

# Conclusions: Peripheral CTA

- Goal of LE CTA:
  - map lesions to symptoms to direct therapy
- Goal of UE CTA:
  - Answer the clinical questions
- **Integrated CM/scan protocol improves consistency**
  - Inject long, scan slow
  - Weight-based CM dosing w/ biphasic injection



# Thanks for your Attention!

- Special thanks to.....  
Dominik Fleischmann, MD  
Kate Hanneman, MD



@CTterrific

Handout: [stanford.edu/~hallett](https://stanford.edu/~hallett)  
choose folder "RSNA2023"

